Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.

He K, Wei Y, Zhao H, Zhang L, Wu F, Liu R, Zhang Y, Wang Y, Chen H, Zeng M, Zhi L, Zhou T, Sheng Z, Wen Q

Open source

DOI
10.1111/dom.71218
Published
2026 Sep 20
Container
Diabetes, obesity & metabolism
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/dom.71218,
  title = {Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.},
  author = {He K and Wei Y and Zhao H and Zhang L and Wu F and Liu R and Zhang Y and Wang Y and Chen H and Zeng M and Zhi L and Zhou T and Sheng Z and Wen Q},
  year = {2026},
  journal = {Diabetes, obesity \& metabolism},
  doi = {10.1111/dom.71218},
  url = {https://doi.org/10.1111/dom.71218}
}

RIS

TY  - JOUR
TI  - Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.
AU  - He K
AU  - Wei Y
AU  - Zhao H
AU  - Zhang L
AU  - Wu F
AU  - Liu R
AU  - Zhang Y
AU  - Wang Y
AU  - Chen H
AU  - Zeng M
AU  - Zhi L
AU  - Zhou T
AU  - Sheng Z
AU  - Wen Q
PY  - 2026
JO  - Diabetes, obesity & metabolism
DO  - 10.1111/dom.71218
UR  - https://doi.org/10.1111/dom.71218
ER  - 

APA

K, H., Y, W., H, Z., L, Z., F, W., R, L., Y, Z., Y, W., H, C., M, Z., L, Z., T, Z., Z, S., & Q, W. (2026). Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.71218

Source records